Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

30 Apr 2022

Abstract excerpt

BACKGROUND: Neuroblastoma is a deadly childhood cancer, and MYCN-amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant. While retinoic acid (RA) is beneficial for some neuroblastoma patients, the cause of RA resistance is unknown. Thus, there remains a need for new therapies to treat neuroblastoma. Here we explored the possibility of combining a MYCN-specific antigene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuroblastoma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35490242
DOI: 10.1186/s13046-022-02367-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastomaPMID 35490242Read ↗

Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistanceSemantic proximity Read ↗

Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell LinesSemantic proximity Read ↗

Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic DifferentiationSemantic proximity Read ↗

Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma CellsSemantic proximity Read ↗

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitorSemantic proximity Read ↗

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastomaSemantic proximity Read ↗

Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppressionSemantic proximity Read ↗

PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13- <i>cis</i> Retinoic Acid–Mediated Differentiation in NeuroblastomaSemantic proximity Read ↗

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaSemantic proximity Read ↗

CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma CellsSemantic proximity Read ↗

PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic DrugsSemantic proximity Read ↗

Sub-micromolar concentrations of retinoic acid induce morphological and functional neuronal phenotypes in SK-N-SH neuroblastoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.